Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.78 |
| ▸ | CA9 | Q16790 | 5/20 | 0.78 |
| ▸ | CA2 | P00918 | 4/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14884779 | 0.87 | CA12 (1.00) | CA12CA9CA2HSD17B10ELANE | |
| SCHEMBL29463843 | 0.87 | CA12 (1.00) | CA12CA9CA2HSD17B10ELANE | |
| SCHEMBL16831385 | 0.87 | CA12 (0.59) | CA12CA9CA2HSD17B10ELANE | |
| SCHEMBL4027170 | 0.84 | CA12 (0.57) | CA12CA9CA2ELANE | |
| SCHEMBL4025830 | 0.84 | CA12 (0.57) | CA12CA9CA2ELANE | |
| SCHEMBL4029124 | 0.78 | MEN1 (0.57) | CA12CA9CA2HSD17B10ELANE | |
| SCHEMBL11453331 | 0.75 | ALDH1A1 (0.77) | CA12CA9CA2HSD17B10MAPT | |
| SCHEMBL23185354 | 0.74 | CA12 (0.78) | CA12CA9CA2ELANENPC1 | |
| SCHEMBL10965136 | 0.73 | CA12 (0.74) | CA12CA9CA2HSD17B10ELANE | |
| SCHEMBL4027171 | 0.73 | CA9 (0.70) | CA12CA9CA2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2025-09-11 | — | — | US | disclosed |
| US-20240294480-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2024-09-05 | — | — | US | disclosed |
| US-11945787-B2 | Substituted imidazoles for preventing and/or treating cell or tissue necrosis | Ela Pharma Ltd (IL) | 2024-04-02 | — | — | US | disclosed |
| EP-4005569-A2 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2022-06-01 | — | — | EP | disclosed |
| US-20210309620-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2021-10-07 | — | — | US | disclosed |
| US-10968185-B2 | Substituted thiazoles for preventing and/or treating cell or tissue necrosis | ELA PHARMA LTD. (IL) | 2021-04-06 | — | — | US | disclosed |
| US-20180312477-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968185-B2 | Substituted thiazoles for preventing and/or treating cell or tissue necrosis | CELA1, CTSV, CTSA | CA12 885/4885CA9 867/4885CA2 803/4885 |
| US-20240294480-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | CA12 351/4885CA9 419/4885CA2 377/4885 |
| US-20180312477-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | CA12 351/4885CA9 419/4885CA2 377/4885 |
| US-11945787-B2 | Substituted imidazoles for preventing and/or treating cell or tissue necrosis | CELA1, CTSA, CPA1 | CA12 472/4885CA9 451/4885CA2 175/4885 |
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | CA12 351/4885CA9 419/4885CA2 377/4885 |
| US-20210309620-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CTSA, CTSG, CELA1 | CA12 328/4885CA9 397/4885CA2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.